Probiotic Trial Data for Infants with Congenital Heart Disease Undergoing Surgery

Zhixuan Zhang's dataset contains results from a randomized, double-blind, placebo-controlled trial conducted between June 2021 and July 2022. It likely contains measurements of intestinal barrier biomarkers and gut microbiota composition from infants aged 1 month to 1 year with congenital heart disease undergoing cardiopulmonary bypass surgery. The data evaluates the protective effect of perioperative probiotic administration.

Use Cases

• Analyze the effect of probiotics on intestinal barrier biomarkers like IFABP, DAO, D-LA, and CRP.
• Compare gut microbiota diversity and composition between probiotic and placebo treatment groups.
• Evaluate clinical outcomes such as diarrhea incidence and time to enteral feeding initiation.
• Assess the relationship between microbial community structure changes and surgical outcomes.

Strengths

• Data originates from a randomized, double-blind, placebo-controlled trial, a rigorous study design.
• The dataset includes multiple biomarker measurements (IFABP, DAO, D-LA, CRP) and fecal microbiota analysis.
• The trial was conducted on a specific patient population (infants 1 month to 1 year with non-cyanosis CHD) over a defined period (June 2021 to July 2022).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is 23.6 KB, indicating a very limited scope and likely small sample size.

Provenance

Source

Zhixuan Zhang via figshare.

Collection Method

Data collected from a clinical trial involving blood and fecal sample analysis.

Time Range

June 2021 to July 2022.

Freshness

Last updated 2026-04-24 04:23:27; freshness should be verified.